Floatz logo

Recombinant Ephb4-Hsa Fusion Protein

Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes

University of Southern Californiaprotein_peptidePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Daunorubicin
Institut de Recherches Internationales Servier
Phase 3BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
ag-120
Institut de Recherches Internationales Servier
Phase 3BB

View all 50 →

Same molecule, other indications

Recombinant Ephb4-Hsa Fusion Protein is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
infiltrating bladder urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →